BSX:NYE-Boston Scientific Corporation (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 38.82

Change

+0.06 (+0.15)%

Market Cap

USD 54.85B

Volume

6.45M

Average Target Price

USD 44.50 (+14.63%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts. Address: 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-03 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABT Abbott Laboratories

-3.35 (-2.73%)

USD217.76B 49.11 25.42
MDT Medtronic plc

+0.08 (+0.07%)

USD158.83B 52.18 28.29
SYK Stryker Corporation

-2.51 (-1.02%)

USD92.32B 58.43 34.26
EW Edwards Lifesciences Corporati..

-2.03 (-2.35%)

USD53.88B 66.37 49.24
ZBH Zimmer Biomet Holdings, Inc

-1.44 (-0.89%)

USD33.50B 814.82 42.48
BIO-B Bio-Rad Laboratories, Inc

N/A

USD17.84B 4.76 3.31
BIO Bio-Rad Laboratories, Inc

-24.35 (-4.12%)

USD17.66B 4.68 3.31
SNN Smith & Nephew plc

-1.00 (-2.54%)

USD17.03B 38.38 20.96
PEN Penumbra, Inc

-13.86 (-4.89%)

USD10.32B 813.79 490.23
INSP Inspire Medical Systems, Inc

-9.86 (-4.08%)

USD6.76B N/A N/A

ETFs Containing BSX

Symbol Name Weight Mer Price(Change) Market Cap
FHH:CA FT AlphaDEX U.S. Health C.. 0.00 % 0.70 %

-0.92 (-2.46%)

USD0.02B
FXH First Trust Health Care A.. 0.00 % 0.61 %

-3.06 (-2.82%)

USD1.44B
IHI iShares U.S. Medical Devi.. 0.00 % 0.42 %

-7.71 (-2.31%)

USD9.21B
LNGR Global X Longevity Themat.. 0.00 % 0.50 %

-0.50 (-1.80%)

USD0.05B
RYH Invesco S&P 500 Equal Wei.. 0.00 % 0.40 %

-4.76 (-1.81%)

USD0.77B
VSL Volshares Large Cap ETF 0.00 % 0.65 %

-0.38 (-0.99%)

USD2.80M
HIG:CA Brompton Global Healthcar.. 0.00 % 0.75 %

-0.28 (-2.94%)

USD0.05B
UTRN Vesper U.S. Large Cap Sho.. 0.00 % 0.75 %

-0.39 (-1.30%)

USD0.06B
GDNA Goldman Sachs Human Evolu.. 0.00 % 0.50 %

N/A

USD0.06B
WELL:LSE HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.19 (-1.67%)

USD0.02B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.98% 60% D- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.98% 60% D- 64% D
Trailing 12 Months  
Capital Gain 0.18% 28% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.18% 28% F 25% F
Trailing 5 Years  
Capital Gain 122.59% 31% F 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 122.59% 31% F 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 14.64% 46% F 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.64% 46% F 83% B
Risk Return Profile  
Volatility (Standard Deviation) 17.82% 77% C+ 47% F
Risk Adjusted Return 82.14% 62% D- 85% B
Market Capitalization 54.85B 88% B+ 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 14.87 82% B- 62% D-
Price/Book Ratio 3.59 56% F 29% F
Price / Cash Flow Ratio 36.37 21% F 9% F
EV/EBITDA 44.67 32% F 11% F
Management Effectiveness  
Return on Equity 29.32% 92% A- 93% A
Return on Invested Capital -0.34% 52% F 29% F
Return on Assets 2.16% 56% F 52% F
Debt to Equity Ratio 59.49% 37% F 58% F
Technical Ratios  
Short Ratio 1.41 80% B- 58% F
Short Percent 1.09% 83% B 82% B-
Beta 0.87 64% D 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector